New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives

Future Oncology

Volumn 6, Issue 4, 2010, Pages 527-537

  Zhang, Dexin ^a   Fan, Daiming ^a,b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b RESEARCH CENTER OF LASER FUSION   (China)

Author keywords

Chemotherapy; Gastric cancer; Molecular targeted therapy; Multidrug resistance

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; APOPTOSIS REPRESSOR WITH CASPASE RECRUITMENT DOMAIN; BETA TUBULIN; CAPECITABINE; CISPLATIN; CYTOCHROME P450; DIHYDROPYRIMIDINE DEHYDROGENASE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; HEAT SHOCK PROTEIN 27; IRINOTECAN; METALLOTHIONEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MIDKINE; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN 1; OXALIPLATIN; PACLITAXEL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SORCIN; THIOREDOXIN; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; UNINDEXED DRUG; VINCRISTINE;

CANCER CELL; CANCER PATIENT; CANCER SURVIVAL; CHEMOSENSITIVITY; DNA DAMAGE; DNA HYBRIDIZATION; DNA REPAIR; DRUG CONCENTRATION; DRUG DETOXIFICATION; DRUG EFFICACY; EFFUSION; GENE EXPRESSION; HUMAN; LOW DRUG DOSE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STOMACH CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; STOMACH NEOPLASMS;

EID: 77950598277     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.21     Document Type: Review

References (86)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74-108 (2005).
2. Arkenau HT: Gastric cancer in the era of molecularly targeted agents: current drug development strategies. J. Cancer Res. Clin. Oncol. 135(7), 855-866 (2009).
3. Brenner H, Rothenbacher D, Arndt V: Epidemiology of stomach cancer. Methods Mol. Biol. 472, 467-477 (2009).
4. Sugano K: Gastric cancer: pathogenesis, screening, and treatment. Gastrointest. Endosc. Clin. N. Am. 18(3), 513-522, ix (2008).
5. Sun P, Xiang JB, Chen ZY: Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br. J. Surg 96(1), 26-33 (2009).
6. Woll E, Devries A, Eisterer W et al.: Chemotherapy in gastric cancer. Anticancer Res. 28(2B), 1213-1219 (2008).
7. Sasako M: Surgery and adjuvant chemotherapy. Int. J. Clin. Oncol. 13(3), 193-195 (2008).
8. Wong R, Cunningham D: Optimising treatment regimens for the management of advanced gastric cancer. Ann. Oncol. 20(4), 605-608 (2009).
9. Szakacs G, Paterson JK, Ludwig JA, Booth- Genthe C, Gottesman MM: Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5(3), 219-234 (2006).
10. Marin JJ, Romero MR, Blazquez AG, Herraez E, Keck E, Briz O: Importance and limitations of chemotherapy among the available treatments for gastrointestinal tumours. Anticancer Agents Med. Chem. 9(2), 162-184 (2009).
11. Koizumi W, Okayasu I, Hyodo I, Sakamoto J, Kojima H: Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Anticancer Drugs 19(8), 819-824 (2008).
12. Mitani Y, Oue N, Matsumura S et al.: REG IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy. Oncogene 26(30), 4383-4393 (2007).
13. Zhao Y, You H, Liu F et al.: Differentially expressed gene profiles between multidrug resistant gastric adenocarcinoma cells and their parental cells. Cancer Lett. 185(2), 211-218 (2002).
14. Yamada M, Tomida A, Yoshikawa H, Taketani Y, Tsuruo T: Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines. Clin. Cancer Res. 2(2), 427-432 (1996).
15. Tsujitani S, Konishi I, Suzuki K et al.: Expression of thymidylate synthase in relation to survival and chemosensitivity in gastric cancer patients. J. Exp. Clin. Cancer Res. 19(2), 189-195 (2000).
16. Choi J, Lim H, Nam DK et al.: Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br. J. Cancer 84(2), 186-192 (2001).
17. Tonnies H, Poland J, Sinha P, Lage H: Association of genomic imbalances with drug resistance and thermoresistance in human gastric carcinoma cells. Int. J. Cancer 103(6), 752-758 (2003).
18. Kang HC, Kim IJ, Park JH et al.: Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin. Cancer Res. 10(1 Pt 1), 272-284 (2004).
19. Yang YX, Xiao ZQ, Chen ZC et al.: Proteome analysis of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR. Proteomics 6(6), 2009-2021 (2006).
20. Yang YX, Chen ZC, Zhang GY, Yi H, Xiao ZQ: A subcelluar proteomic investigation into vincristine-resistant gastric cancer cell line. J. Cell. Biochem. 104(3), 1010-1021 (2008).
21. Takahashi T, Saikawa Y, Nakamura R et al.: Dynamic alteration of gene expression induced by anticancer-agent exposure in gastric cancer cell lines. Oncology Rep. 21(2), 451-459 (2009).
22. Takaishi S, Okumura T, Tu S et al.: Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27(5), 1006-1020 (2009).
23. Liu H, Li N, Yao L et al.: Prediction of doxorubicin sensitivity in gastric cancers based on a set of novel markers. Oncol. Rep. 20(4), 963-969 (2008).
24. Tanaka T, Tanimoto K, Otani K et al.: Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int. J. Cancer 111(4), 617-626 (2004).
25. Yoshida K, Tanabe K, Ueno H et al.: Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study. Gastric Cancer 6(Suppl. 1), 82-89 (2003).
26. Varadhachary G, Ajani JA: Preoperative and adjuvant therapies for upper gastrointestinal cancers. Expert Rev. Anticancer Ther. 5(4), 719-725 (2005).
27. Ajani JA: Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel. Expert Opin. Pharmacother. 7(12), 1627-1631 (2006).
28. Wallner J, Depisch D, Gsur A, Gotzl M, Haider K, Pirker R: MDR1 gene expression and its clinical relevance in primary gastric carcinomas. Cancer 71(3), 667-671 (1993).
29. Gurel S, Yerci O, Filiz G et al.: High expression of multidrug resistance-1 (MDR-1) and its relationship with multiple prognostic factors in gastric carcinomas in patients in Turkey. J. Int. Med. Res. 27(2), 79-84 (1999).
30. Choi JH, Lim HY, Joo HJ et al.: Expression of multidrug resistance-associated protein1, P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br. J. Cancer 86(10), 1578-1585 (2002).
31. Tomonaga M, Oka M, Narasaki F et al.: The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers. Jpn. J. Cancer Res. 87(12), 1263-1270 (1996).
32. Kellner U, Hutchinson L, Seidel A et al.: Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein. Int. J. Cancer 71(5), 817-824 (1997).
33. Ross DD, Yang W, Abruzzo LV et al.: Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Natl Cancer Inst. 91(5), 429-433 (1999).
34. Fan K, Fan D, Cheng LF, Li C: Expression of multidrug resistance-related markers in gastric cancer. Anticancer Res. 20(6C), 4809-4814 (2000).
35. Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K: Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S- transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Cancer Invest. 26(4), 344-351 (2008).
36. Yeh KH, Chen CL, Shun CT et al.: Relatively low expression of multidrug resistance-1 (MDR-1) and its possible clinical implication in gastric cancers. J. Clin. Gastroenterol. 26(4), 274-278 (1998).
37. Yamauchi M, Kumazawa H, Satta T et al.: Prediction of doxorubicin resistance in gastrointestinal cancer by P-glycoprotein staining. Eur. J. Cancer 28A(8-9), 1422-1427 (1992).
38. Kang MS, Kim HS, Han JA, Park SC, Kim WB, Park JG: Characteristics of human gastric carcinoma cell lines with induced multidrug resistance. Anticancer Res. 17(5A), 3531-3536 (1997).
39. Endo K, Maehara Y, Kusumoto T, Ichiyoshi Y, Kuwano M, Sugimachi K: Expression of multidrug-resistance-associated protein (MRP) and chemosensitivity in human gastric cancer. Int. J. Cancer 68(3), 372-377 (1996).
40. Satta T, Isobe K, Yamauchi M, Nakashima I, Takagi H: Expression of MDR1 and glutathione S transferase-pi genes and chemosensitivities in human gastrointestinal cancer. Cancer 69(4), 941-946 (1992).
41. Schipper DL, Wagenmans MJ, Peters WH, Wils JA, Wagener DJ: Glutathione S-transferases and iododeoxyuridine labelling index during chemotherapy of gastric cancer. Anticancer Res. 20(3A), 1705-1710 (2000).
42. Monden N, Abe S, Sutoh I, Hishikawa Y, Kinugasa S, Nagasue N: Prognostic significance of the expressions of metallothionein, glutathione-S-transferase- pi, and P-glycoprotein in curatively resected gastric cancer. Oncology 54(5), 391-399 (1997).
43. Okuyama T, Maehara Y, Endo K et al.: Expression of glutathione S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin. Cancer 74(4), 1230-1236 (1994).
44. Filomeni G, Aquilano K, Rotilio G, Ciriolo MR: Glutathione-related systems and modulation of extracellular signal-regulated kinases are involved in the resistance of AGS adenocarcinoma gastric cells to diallyl disulfide-induced apoptosis. Cancer Res. 65(24), 11735-11742 (2005).
45. Niitsu Y, Takahashi Y, Saito T et al.: Serum glutathione-S-transferase-pi as a tumor marker for gastrointestinal malignancies. Cancer 63(2), 317-323 (1989).
46. Peters WH, Wormskamp NG, Thies E: Expression of glutathione S-transferases in normal gastric mucosa and in gastric tumors. Carcinogenesis 11(9), 1593-1596 (1990).
47. Kodera Y, Akiyama S, Isobe K et al.: Expression of pi-glutathione S-transferase gene (GSTP1) in gastric cancer: lack of correlation with resistance against cis-diamminedichloroplatinum (II). Eur. J. Cancer 30A(14), 2158-2162 (1994).
48. Kang SH, Bang YJ, Im YH et al.: Transcriptional repression of the transforming growth factor-b type I receptor gene by DNA methylation results in the development of TGF-b resistance in human gastric cancer. Oncogene 18(51), 7280-7286 (1999).
49. Tanner M, Hollmen M, Junttila TT et al.: Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 16(2), 273-278 (2005).
50. Nagai S, Yamauchi M, Andoh T et al.: Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (a new derivative of camptothecin). J. Surg. Oncol. 59(2), 116-124 (1995).
51. Son YS, Suh JM, Ahn SH et al.: Reduced activity of topoisomerase II in an adriamycin-resistant human stomach-adenocarcinoma cell line. Cancer Chemother Pharmacol. 41(5), 353-360 (1998).
52. Matsuhashi N, Saio M, Matsuo A, Sugiyama Y, Saji S: The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: time- and p53 expression-dependency of anti-cancer drugs. Oncology Rep. 14(3), 609-615 (2005).
53. Cascinu S, Graziano F, Del Ferro E et al.: Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer 83(9), 1917-1922 (1998).
54. Yeh KH, Shun CT, Chen CL et al.: Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapy. Hepatogastroenterology 46(25), 610-615 (1999).
55. Ning H, Li T, Zhao L et al.: TRF2 promotes multidrug resistance in gastric cancer cells. Cancer Biol. Ther. 5(8), 950-956 (2006).
56. Chun JH, Kim HK, Kim E et al.: Increased expression of metallothionein is associated with irinotecan resistance in gastric cancer. Cancer Res. 64(14), 4703-4706 (2004).
57. Wang JX, Li Q, Li PF: Apoptosis repressor with caspase recruitment domain contributes to chemotherapy resistance by abolishing mitochondrial fission mediated by dynamin-related protein-1. Cancer Res. 69(2), 492-500 (2009).
58. Griffiths EA, Pritchard SA, Welch IM, Price PM, West CM: Is the hypoxia-inducible factor pathway important in gastric cancer? Eur. J. Cancer 41(18), 2792-2805 (2005).
59. Skvortsova I, Skvortsov S, Haidenberger A et al.: Effects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in vitro. J. Chemother 16(4), 372-380 (2004)
60. Liu L, Ning X, Sun L et al.: Hypoxia-inducible factor-1 a contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci. 99(1), 121-128 (2008).
61. Liang J, Bai F, Luo G et al.: Hypoxia induced overexpression of PrP(C) in gastric cancer cell lines. Cancer Biol. Ther. 6(5), 769-774 (2007).
62. Rohwer N, Welzel M, Daskalow K et al.: Hypoxia-inducible factor 1a mediates anoikis resistance via suppression of a5 integrin. Cancer Res. 68(24), 10113-10120 (2008).
63. Liu L, Sun L, Zhang H et al.: Hypoxia-mediated upregulation of MGR1-AG/37LRP in gastric cancers occurs via hypoxia-inducible-factor 1-dependent mechanism and contributes to drug resistance. Int. J. Cancer 124(7), 1707-1715 (2009).
64. Michl P, Downward J: Mechanisms of disease: PI3K/Akt signaling in gastrointestinal cancers. Z. Gastroenterol. 43(10), 1133-1139 (2005).
65. Han Z, Hong L, Han Y et al.: Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax. J. Exp. Clin. Cancer Res. 26(2), 261-268 (2007). (Pubitemid 47025290)
66. Oki E, Baba H, Tokunaga E et al.: Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int. J. Cancer 117(3), 376-380 (2005).
67. Yu HG, Ai YW, Yu LL et al.: Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int. J. Cancer 122(2), 433-443 (2008).
68. Zhang Y, Qu X, Hu X et al.: Reversal of P-glycoprotein-mediated multi-drug resistance by the E3 ubiquitin ligase Cbl-B in human gastric adenocarcinoma cells. J. Pathol. 218(2), 248-255 (2009).
69. Blower PE, Chung JH, Verducci JS et al.: MicroRNAs modulate the chemosensitivity of tumor cells. Mol. Cancer Ther. 7(1), 1-9 (2008).
70. Yang H, Kong W, He L et al.: MicroRNA expression profiling in human ovarian cancer: mir-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68(2), 425-433 (2008).
71. Zheng T, Wang J, Chen X, Liu LX: Role of microRNA in anticancer drug resistance. Int. J. Cancer 126(1), 2-10 (2009).
72. Xia L, Zhang D, Du R et al.: Mir-15b and mir-16 modulate multidrug resistance by targeting Bcl2 in human gastric cancer cells. Int. J. Cancer 123(2), 372-379 (2008).
73. Chen CC, Chen LT, Tsou TC et al.: Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil. Br. J. Cancer 97(3), 334-344 (2007).
74. Pinto C, Di Fabio F, Siena S et al.: Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann. Oncol. 18(3), 510-517 (2007).
75. Han SW, Oh DY, Im SA et al.: Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br. J. Cancer 100(2), 298-304 (2009).
76. Rao S, Starling N, Cunningham D et al.: Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br. J. Cancer 99(6), 868-874 (2008).
77. Rojo F, Tabernero J, Albanell J et al.: Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J. Clin. Oncol. 24(26), 4309-4316 (2006).
78. Dragovich T, Mccoy S, Fenoglio-Preiser CM et al.: Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J. Clin. Oncol. 24(30), 4922-4927 (2006).
79. Gong SJ, Jin CJ, Rha SY, Chung HC: Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett. 214(2), 215-224 (2004).
80. Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N, Kitano S: Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int. J. Oncol. 27(3), 681-685 (2005).
81. Kim JW, Kim HP, Im SA et al.: The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett. 272(2), 296-306 (2008).
82. Motwani M, Rizzo C, Sirotnak F, She Y, Schwartz GK: Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol. Cancer Ther. 2(6), 549-555 (2003).
83. Fujita T, Doihara H, Washio K et al.: Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells. Anticancer Drugs 18(6), 677-686 (2007).
84. Shah MA, Ramanathan RK, Ilson DH et al.: Multicenter Phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J. Clin. Oncol. 24(33), 5201-5206 (2006).
85. Cortes-Funes H, Rivera F, Ales I et al.: Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification. J. Clin. Oncol. 25(18 Suppl.), 4613 (2007).
86. Van Cutsem E, Kang Y, Chung H et al.: Efficacy results from the ToGa trial: a Phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J. Clin. Oncol. 27(18S), LBA4509 (2009).